Statement: most participants in the first and second cohort of the primary clinical trial failed to attain 5 years of disease-free survival.
Primary_evidence: Outcome Measurement:    Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer   The percentage of patients alive and cancer-free.   Time frame: 5 years Results 1:    Arm/Group Title: Group 1: TAC X 6   Arm/Group Description: Doxorubicin, cyclophosphamide, and docetaxel.   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles   Docetaxel: 75 mg/m2 IV every 21 days for 6 cycles   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles   Overall Number of Participants Analyzed: 1610   Measure Type: Number   Unit of Measure: percentage of patients  80.1        (78.0 to 82.0) Results 2:    Arm/Group Title: Group 2: AC X 4 Then P X 4   Arm/Group Description: Doxorubicin, cyclophosphamide, and paclitaxel   Cyclophosphamide: Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles   Paclitaxel: 175 mg/m2 IV every 14 days for 4 cycles   Doxorubicin: Group 1: 50 mg/m2 IV every 21 days for 6 cycles   Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles   Overall Number of Participants Analyzed: 1618   Measure Type: Number   Unit of Measure: percentage of patients  82.2        (80.2 to 84.0)